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Abstract: Background and Objectives: Data emerging from the Women’s Health Initiative (WHI) study
point toward an association between menopausal hormone therapy (MHT) and cardiovascular (CV)
risk. However, post hoc subgroup analyses stratifying participants according to their age and time
since menopause, have opened the way to a better understanding of the relationship between estrogen
and CV risk. The aim of this review was to revise the current literature and evaluate the CV risk
or benefit following administration of MHT considering several factors such as MHT timing, dose,
route of administration, and formulation. Materials and Methods: An electronic databases search
of MEDLINE (PubMed), Cochrane Central Register of Controlled Trials, Web of Science, SCOPUS,
congress abstracts, and Grey literature (Google Scholar; British Library) was performed, with the
date range from each database’s inception until June 2019. All the studies evaluating MHT and
cardiovascular risk, including thromboembolism or stroke, were selected. Results: Timing of MHT
initiation was shown to be a critical factor in CV risk assessment. In concordance with the “timing
hypothesis”, healthy symptomatic women who initiated MHT when aged younger than 60 years,
or who were within 10 years of menopause onset, have demonstrated a reduction in both coronary
heart disease (CHD) risk and all-cause mortality. In particular, MHT therapy was associated with
improvement of subclinical signs of atherosclerosis. Venous thromboembolism (VTE) risk is reduced
when low doses of oral estrogen are used. Moreover, transdermal hormonal application significantly
reduces CV risk compared with oral administration. MHT impact on the CV system is influenced
by either factors inherent to the specific regimen, or factors inherent to the specific patient. Hence,
individualization of care is necessary. Conclusion: CV risk calculation should be considered by
clinicians in order to exclude patients with high CV risk, in whom MHT is contraindicated. Assessing
risks and benefits in a patient-centered approach according to individual’s features, health status, and
personal preferences is important in order to realize a safe and effective treatment.
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1. Introduction
Menopausal hormonal therapy (MHT) ameliorates vasomotor symptomatology, prevents bone
loss, and treats estrogen deficiency-related genitourinary symptoms [1]. As such, it is an FDA-approved
therapy for these symptoms [1,2]. Whether MHT confers harmful or beneficial effects on cardiovascular
(CV) system is controversial. Atherosclerosis and clinical cardiovascular diseases (CVD) tend to
appear in women at an older age in comparison with men [3], particularly in the postmenopausal
period. Several observational studies have shown that patients taking MHT have reduced CVD risk.
Specifically, it was presumed that estrogen serves as a CV protective factor and thus, it was initially
assumed that after menopause, MHT can replenish the decline in circulating estrogen and, along with
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symptomatology relief, can reduce long-term CVD risk [4–8]. Estrogen acts by binding to various
receptors and activating multiple signaling pathways [9]. Its protective effects are attributed to serum
lipid concentrations modulation [10], as well as estrogen’s direct actions on the vasculature, including
vasodilation and inhibition of the response to vascular injury [11]. However, later data emerging from
the Women’s Health Initiative (WHI) study [12,13], pointing toward an association between estrogen
therapy and CV risk, have challenged this widespread belief and the use of MHT was dramatically
reduced [14].
2. Materials and Methods
2.1. Data Sources
We searched MEDLINE (PubMed), Cochrane Central Register of Controlled Trials, Web of Science,
SCOPUS, and Grey literature (Google Scholar; British Library) from January 1980 to June 2019. We used
the terms “menopausal hormone replacement therapy”, “hormone replacement therapy”, “estrogen
therapy”, “Estrogen, progesterone menopausal therapy”, “Tibolone”, and “T-sec” as text words and as
appropriate medical subject headings or equivalent subject headings/thesaurus terms. These terms
were combined with “cardiovascular risk”, “thromboembolism”, and “stoke”. The reference lists of all
available primary studies were reviewed to identify additional relevant citations.
2.2. Screening of Abstract for Eligibility
Abstracts and titles identified from the search were screened by 3 investigators. Disagreements
about the inclusion or exclusion of studies were primarily solved by consensus, and when this was not
possible, a fourth reviewer resolved them.
2.3. Study Selection and Eligibility Criteria
A set of specific criteria were used for selection of literature: Randomized controlled trials
(RCT); prospective or retrospective cohort studies; reviews and meta analyses; international societies’
guidelines; studies with outcome measures including cardiovascular risks or benefits; and studies with
evaluation of various types of MHT, route of administration, formulation, and dose. Only studies
written in English with an available abstract were accepted.
3. Results
3.1. MHT: Cardiovascular Risk and Benefit Overview
The WHI [12,13] was a large, long-term RCT that enrolled postmenopausal women aged 50–79 years
between the years 1993–1998 and was designed to evaluate the risks and benefits of hormonal therapy
for the prevention of chronic diseases, including the effects on CVD. The WHI trial randomized
women to either combination MHT with estrogen/progestin (conjugated estrogen (CE) 0.625 mg and
medroxyprogesterone acetate 2.5 mg/day) or placebo. After a mean follow-up of 5.2 years, this study
arm was discontinued due to an increased risk of coronary heart disease (CHD) HR 1.29 (0.85–1.07),
stroke HR 1.41 (0.86–2.31), venous thromboembolism (VTE) HR 2.11 (1.26–3.55), and composite CVD
risk HR 1.22 (1.09–1.36). An increase in CV events was reported in the extended follow-up post-stopping
phase as well [15]. Similarly, no reduction in CHD was shown in the Heart and Estrogen/Progestin
Replacement Study (HERS) [16] and the subsequent follow up study (HERSII) [17] in patients with
known CHD receiving conjugated equine estrogen and medroxyprogesterone acetate. WHI clinical
trials concluded that hormonal therapy does not confer cardiac protection and overall risks in healthy
postmenopausal women exceed benefits.
Some possible factors influencing the negative results of WHI were identified. The trial recruited
women with a mean age at enrollment of 63 years, having 12 years mean time since menopause. Only
a limited number of women had vasomotor symptoms, many women had CV risk factors at entry
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(approximately 35% had hypertension), and some had already documented CV events. Moreover,
the hormonal doses that were used in the trial are currently considered to be high [18,19].
Thus, it has been stated that the WHI results may not be applied for younger symptomatic
menopausal women and/or patients with a more recent onset of menopause. Therefore, post hoc
subgroup analyses stratifying participants according to their age and time since menopause were
performed [20]. This study noted a trend toward both CHD risk and total mortality reduction in younger
women within the first 10 years after menopause. The explanation of these trends has gained the term
“the timing hypothesis” [21,22], which states that MHT given in healthy women does not increase CHD
risk and possesses the highest cardiovascular benefits when started soon after the onset of menopause.
Timing of hormonal therapy initiation was shown to be a critical factor in CV risk assessment, not only
in secondary analysis of the WHI study [20,23] but in other studies as well [24–28]. In concordance
with the timing hypothesis, a 2015 Cochrane review evaluating randomized controlled trials (RCTs)
comparing hormone therapy with placebo demonstrated a reduction in both CHD risk (composite
of death from cardiovascular causes and nonfatal myocardial infarction) and all-cause mortality in
younger women who had commenced therapy less than 10 years since menopause or were less than
60 years old [29]. In this group of participants, an increased risk of venous thromboembolism was
still noted. It is likely that younger women have a healthier heart and less subclinical atherosclerosis
at baseline and hence lower CVD risk with hormonal therapy when compared to older women
with increased duration of menopause. Indeed, approximately 1000 women aged 50–59 years who
participated in the WHI study under the unopposed estrogen treatment arm were evaluated in
the WHI Coronary Artery Calcium Study [30]. Computed tomography heart imaging was used to
evaluate the coronary artery calcium burden, which was shown to be lower in women assigned to
estrogen than in those assigned to placebo (83.1 vs. 123.1; P = 0.02). Furthermore, in order to assess
MHT effect on atherosclerosis progression, surrogate markers of CVD risk such as measurements of
carotid intima-media thickness (CIMT) and Coronary Arterial Calcification (CAC) were done in other
important clinical trials [30–32].
In the Early vs. Late Intervention Trial with Estradiol (ELITE) study [32], 643 healthy postmenopausal
women were grouped according to time since menopause (<6 years past menopause or ≥10 years past
menopause). The women were randomly assigned to receive either oral 17 beta-estradiol (1 mg/day
plus progesterone 45 mg vaginal gel administered sequentially in women with a uterus) or placebo for
a median of five years. This trial has demonstrated that women who received estradiol had lower rates
of subclinical atherosclerosis progression, as measured by the rate of change in CIMT, only when therapy
was started within 6 years after menopause, but not if started ≥ 10 years after.
The Kronos Early Estrogen Prevention Study (KEEPS) [33,34] has evaluated the hormonal therapy
effect on CIMT and CAC as a surrogate to atherosclerosis progression. In the study, 727 healthy women
aged 42 to 58 years who were within 3 years after menopause were randomized to treatment arm or
placebo. Treatment options were either conjugated equine estrogen (0.45 mg/d) or transdermal estradiol
patches (50 mcg/d). Both estrogens were combined with cyclic oral micronized progesterone (200 mg
for 12 days each month). No effect on CIMT progression was seen with treatment when compared to
placebo. Authors have suggested that these results are due to the short duration of the trial as well as
the young age and low risk profile of the participating women [35]. The discrepancy between the ELITE
and KEEPS results can be further explained by the low-dose treatment used in the latter (1 mg/d and
0.45 mg/d, respectively) [32–34]. Consideration of the WHI subgroups analysis, along with multiple
observational studies in the “pre WHI era” and “post WHI era” [36,37] as well as KEEPS and ELITE
findings, has opened the way to a better understanding of the relationship between estrogen and CV
risk. These data indicate a low-risk, favorable benefit–risk profile for young symptomatic women
in early menopause who use MHT in the absence of contraindications [38–41]. Accordingly, current
guidelines [1,42] suggest that benefits are most likely to outweigh risks for healthy symptomatic women
who initiate MHT when aged younger than 60 years or who are within 10 years of menopause onset.
MHT should not be used for the primary or secondary prevention of coronary heart disease [43,44].
Medicina 2019, 55, 571 4 of 12
For women aged younger than 60 years or who are within 10 years past menopause onset,
considering MHT for menopausal symptom relief, the endocrine society suggest evaluating the
baseline risk of CVD and taking this risk into consideration when advising for or against MHT and
when selecting type, dose, and route of administration [42]. Risk calculation by modification of the
American College of Cardiology (ACC)/American Heart Association (AHA) 10 year CVD risk [45] with
stratifications according to years since menopause is available in the Menopause Decision Support
Algorithm [46]. Table 1 summarizes the principle statement of current guidelines.
Table 1. Data summarized from North American Menopause Society 2017 guidelines [1] and Endocrine
Society Clinical Practice Guideline [42].





- Menopausal hormone therapy
(MHT) is a safe and effective
treatment option of menopausal
symptoms when introduced in
healthy postmenopausal women
that are within 10 years of
menopause onset or aged younger
than 60 years; some data suggest
reduced risk of CHD in this age
range.
- It is important to evaluate the
baseline risk of cardiovascular
disease (CVD) and to consider this
risk when advising for or against
MHT and when selecting type,
dose, and route of administration
- For women at high risk of CVD,
MHT is not recommended.
-For women with moderate risk of
CVD, transdermal estradiol
should be offered as first-line
treatment, alone for women
without a uterus, or combined
with micronized progesterone (or
another progestogen that does not
adversely modify metabolic
parameters) for women with a
uterus.
- In women who start using MHT
more than 10 years from
menopause onset, and evidently
by 20 years, there is potential for
increased risk of CHD.
-Hormone therapy is not FDA
indicated for primary or
secondary cardioprotection.
- For women at increased
risk of VTE who request
MHT, a nonoral route of




-For women with a






- A meta-analysis of
randomized controlled
trials (RCTs) of women
who initiate MHT found
no increased risk of
stroke in women aged
younger than 60 years or





- Lower-dose oral as well
as lower-dose
transdermal therapy has







mortality in women who
initiate MHT when aged
younger than 60 years
and/or are within 10
years from menopause
onset.
- No protective effect was
found in women with
initiation more than 10
years from menopause
onset.
Personal and familial risk of CVD, stroke, and VTE should be considered when initiating MHT.
* Evidence based on observational studies and meta-analyses, although RCT data are still lacking.
3.2. MHT Dose, Route of Administration, and Formulation
In addition to personal preferences, the individual patient’s characteristics and clinical status might
come into play while choosing one route of treatment delivery or specific formulation over another.
In particular, the dose, estro-progestin/progesterone association, and route of administration must
be taken into account.
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3.3. Dose
The therapeutic goal should be to use the most appropriate, often lowest, effective dose of systemic
ET (estrogen therapy) consistent with treatment objectives [1]. A prospective, observational cohort
study investigating more than 70,000 healthy postmenopausal women found that MHT is associated
with a reduction in major coronary events risk compared with never-users. Importantly, similar
reduction was observed with those taking 0.3 mg of oral conjugated estrogen daily and those taking
the standard dose of 0.625 mg. However, estrogen at daily doses of 0.625 mg or greater (alone or in
combination with progestin) may increase risk for stroke [4]. In addition, while low-dose MHT (such as
0.3 mg conjugated estrogen) was found to have comparable effects on lipoproteins, flow-mediated
dilation, and plasminogen activator inhibitor type 1 antigen levels, it had fewer effects on coagulation
and inflammatory markers than standard-dose therapy [47]. VTE risk may be reduced with lower
doses of oral estrogen than higher doses [48].
3.4. Route of Administration
MHT can be administered orally and nonorally (transdermal, vaginal, and intrauterine). Only
oral MHT undergoes first-pass metabolism. The first-pass effect can produce benefits including
reductions in low-density lipoprotein cholesterol and increases in high-density lipoprotein cholesterol,
however, unwanted effects are triglycerides increase and coagulation activation [49,50]. Transdermal
administration, by avoiding the hepatic effect, has lower impact on coagulation factors hemostasis [51].
Change in lipid profile was observed in a KEEPS trial [33] in those who had oral conjugated equine
estrogens. Studies have demonstrated a lower risk of VTE and stroke with transdermal estrogen
(at standard doses) compared with oral [48,52–55]. For example, a multicenter hospital-based
case-control study of postmenopausal women, enrolled 155 consecutive cases with a first documented
episode of idiopathic VTE and 381 matching controls. The odds ratio for VTE in current users of
oral and transdermal estrogen compared with nonusers was 3.5 (95% CI 1.8–6.8) and 0.9 (0.5–1.6),
respectively. Estimated risk for VTE in current users of oral ET compared with transdermal ET users
was 4.0 (1.9–8.3). These data suggest that transdermal ET is safer than oral ET regarding thrombotic
risk [56].
4. Formulation
Estrogen alone and estro-progestin administration have different impacts on the cardiovascular risk.
Patients who underwent hysterectomy (surgical removal of uterus) for gynecological indications can avoid
the administration of progesterone or progestins, which are given in order to decrease the risk of endometrial
hyperplasia and subsequent endometrial cancer in women with a uterus. The WHI trials [12,13] have
suggested that unopposed estrogen administration have less adverse outcomes in comparison with
estrogen plus progestin for treating postmenopausal women. Nevertheless, the knowledge regarding the
properties of the different progestins compounds is important. Synthetic medroxyprogesterone acetate
is vasoconstrictive, however, natural progesterone possesses vasodilatory properties and might have
a positive effect on blood pressure [57–60]. Drospirenone has antimineralocorticoid diuretic effects and
may decrease blood pressure and weight [61–63]. Progesterone has a beneficial effect on lipid profile [64].
While non pregnane progestins were associated with excess risk of VTE, no increased risk was noted with
medroxyprogesterone acetate and micronized progesterone [65].
Several studies that evaluated the thromboembolic risk of MHT have included separate analyses
of estrogen-only and combined estrogen/progestin. However, even if according to available data they
confer different risks, it is still inconclusive [66].
Furthermore, a 2008 meta-analysis did not observe a difference in the thrombogenicity of
estrogen-only versus estrogen/progestin HRT (HR 2.2, 95% CI, 1.6–3.0, and HR 2.6, 95% CI, 2.0–3.2,
respectively) [67]. Similarly, LITE investigators calculated similar relative risks for estrogen/progestin
(1.6, 95% CI, 1.0–2.6) and estrogen alone (1.6, 95% CI 1.1–2.4) [68]. Likewise, the WISDOM trial did
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not find a difference in VTE risk between combination and estrogen-only HRT, though it may have
been insufficiently powered to do so [69]. On the other hand, a prospective case-control study has
demonstrated that estrogen/progestin caused an increased relative risk of 2.7 (95% CI 1.4–5.1) in
VTE, whereas estrogen alone did not (RR 1.2, 95% CI 0.6–2.6) [70]. Similarly, another study found
that combination hormonal therapy had an odds ratio of 1.6 (95% CI 1.1–2.3) of VTE compared to
estrogen-only use [71]. The WHI found an increased risk of VTE in women taking estrogen/progestin
replacement [72], but not in those taking estrogens alone [13].
4.1. Tibolone and Cardiovascular Effects
Tibolone is a synthetic steroid used for the treatment of climacteric symptoms. It is classified
as a selective tissue estrogenic activity regulator (STEAR) even though it combines estrogenic,
progestogenic, and androgenic activity and has tissue-specific properties [73]. Tibolone has complex
effects on lipid profile and, along with beneficial effects on a few cardiovascular markers (total
cholesterol, LDL, lipoprotein (a) levels), it seems to decrease HDL cholesterol [74–77]. Moreover, it is
associated with C-reactive protein elevation and modulation of other inflammatory markers [77,78].
Despite these features, tibolone appears to exert antiatherogenic properties and was found to reduce
atherosclerosis progression in animals [79,80] and in humans [81,82]. VTE risk does not increase with
tibolone [83–85]. Nevertheless, tibolone may increase the risk of stroke in older women [84,86].
In a randomized study designed to test the tibolone efficacy on bone metabolism, 4538 osteoporotic
women, who were between the ages of 60 and 85 years received once-daily tibolone (at a dose of
1.25 mg) or placebo. Tibolone reduced the risk of fracture and breast cancer, but increased the risk of
stroke in these older women. The overall number of adverse events was small, and no increased risk
of venous thromboembolism or coronary events was observed [84].
4.2. Tissue-Selective Estrogen Complex (TSEC) and Cardiovascular Effects
Conjugated estrogen-bazedoxifene (CE/BZA) is currently the only approved TSEC for managing
VMS and osteoporosis prevention in postmenopausal women. BZA, a selective estrogen receptor
modulator (SERM), protects against estrogenic effects on the uterus and thus may be used for
non-hysterectomized women without the need for progestin administration.
Most of the evidence that has led to CE/BZA approval is derived from a series of phase III trials
named SMART (selective estrogens, menopause, and response to therapy) [87–90]. Cardiovascular
safety of CE/BZA was assessed by a meta-analysis of five SMART trials [91]. Rates of stroke, VTE,
and CHD-related events were comparable to placebo in healthy postmenopausal women who were
given at least one dose of CE 0.45 or CE 0.625 mg with BZA 20 mg for up to two years. However,
BZA effect on venous thromboembolism risk remain unclear, especially because a previous five-year
phase III study on BZA alone did show more frequent VTE [92]. Another pooled analysis of three
SMART trials reported mostly favorable changes in lipid parameters (total cholesterol, LDL, HDL),
while triglycerides were significantly increased compared to placebo [93].
5. Conclusions
MHT impact on the CV system is influenced by either factors inherent to the specific regimen
(route of administration, formulation, dose, and duration of use) or factors inherent to the specific
patient (other CV risk factors, comorbidities, and age at menopause onset and at therapy initiation).
Hence, individualization of care is necessary. Healthy symptomatic postmenopausal women should
initiate MHT when aged younger than 60 years or who are within 10 years of menopause onset. MHT
should be prescribed at the lowest effective dose and the transdermal route is preferred in some
cases. A clinician should consider the risks and benefits in a patient-centered approach, assessing the
individual’s features, health status, and preferences.
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